StreetInsider.com News Articles

Form 8-K Beyond Air, Inc. For: May 28

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584283.html

Form 8-K Beyond Air, Inc. For: May 28

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584283.html

Beyond Air gets Nasdaq extension to regain bid price compliance by July 31

Mon, 01 Jun 2026 08:03:38 -0400

Beyond Air Inc. (NASDAQ: XAIR) received approval from a Nasdaq hearing panel to continue its listing on the exchange, according to a company statement. The medical device company must regain compliance with the exchange's minimum bid price requirement by July 31, 2026.

The company remains compliant with all other Nasdaq listing requirements. Beyond Air focuses on nitric oxide-based treatments for respiratory illnesses and other conditions.

"We appreciate the Panel's thoughtful review and support of our compliance plan," said Robert Goodman, chief executive officer. "This decision provides us with the time needed to complete the steps necessary to regain compliance while we remain

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

Mon, 01 Jun 2026 08:00:00 -0400

GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC’s (“Nasdaq” or the “Exchange”) Listing Rule 5550(a)(2) (the “Bid Price Rule”) by July 31, 2026. The Company is fully compliant with all other continued listing requirements.

“We appreciate the Panel’s

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

Mon, 01 Jun 2026 08:00:00 -0400

“We appreciate the Panel’s

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

Mon, 01 Jun 2026 08:00:00 -0400

“We appreciate the Panel’s

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

Mon, 01 Jun 2026 08:00:00 -0400

“We appreciate the Panel’s

Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: Alyeska Investment Group, L.P.

Fri, 15 May 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260515/26507392.html

Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: Alyeska Investment Group, L.P.

Fri, 15 May 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260515/26507392.html

Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:22:00 -0400

si-local-file:///var/storage/secattach/20260515/26498872.html

Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:22:00 -0400

si-local-file:///var/storage/secattach/20260515/26498872.html

Form DEF 14A Beyond Air, Inc. For: May 05

Tue, 05 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260505/26435537.html

Form DEF 14A Beyond Air, Inc. For: May 05

Tue, 05 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260505/26435537.html

Form PRE 14A Beyond Air, Inc. For: Apr 24

Fri, 24 Apr 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260424/26366658.html

Form PRE 14A Beyond Air, Inc. For: Apr 24

Fri, 24 Apr 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260424/26366658.html

Beyond Cancer presents Phase 1 UNO trial survival data at AACR 2026

Mon, 20 Apr 2026 08:02:03 -0400

Beyond Cancer Ltd., a subsidiary of Beyond Air Inc. (NASDAQ: XAIR), presented updated survival data from its Phase 1 trial of ultra-high concentration nitric oxide (UNO) at the American Association for Cancer Research Annual Meeting 2026 in San Diego.

The Phase 1 trial enrolled 10 heavily pretreated patients with unresectable cutaneous or subcutaneous tumors, including breast cancer, squamous cell carcinoma, and melanoma. Patients had received a median of four prior systemic therapies and 11 total cancer-directed treatments. Six patients received 25,000 ppm UNO and four patients received 50,000 ppm UNO through intratumoral injection.